Soluble guanylate cyclate activators for treating systemic sclerosis

A method for treating a patient with systemic sclerosis, comprising administering to the patient a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I),

• wherein:
• A is a 5-7 membered saturated heterocyclyl group containing one nitrogen and optionally one oxygen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two groups selected from C1-3alkyl and oxo;
• R1 is C1-4 alkyl optionally substituted with a methoxy group;
• R2 is selected from H, F, Cl, C1-3alkyl, —CN, -OMe and —CF3;
• R3 is selected from H and —CH3;
• R4 is selected from H, F, —CH3 and -OMe;
• R5 is selected from H, Cl, —CH3, —CH2CH3, —CF3, F, and -OMe;
• R6 is bonded to the nitrogen on A and is selected from H, C1-6alkyl, —(CH2)nC3-6cycloalkyl, —C(O)C1-6alkyl, —(CH2)n heterocyclyl, —(CH2)n aryl —(CH2)n heteroaryl, —SO2aryl, S02C1-6alkyl wherein said C1-6alkyl, —(CH2)n heterocyclyl, —(CH2)n cycloalkyl, —(CH2)n aryl and —(CH2)n heteroaryl are optionally substituted with one to four groups independently selected from C1-3alkyl, halogen, C1-3alkoxy, —CF3, —OH, oxo, —(CH2)1-3OH(CH2)2-3OH, and —SO2CH3;
• R7 is selected from H, —CH3, —CH2CH3, —CF3, F, and —CN;
• n is 0, 1 or 2
• or a pharmaceutically acceptable salt thereof.